KR20050037409A - 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 - Google Patents
미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 Download PDFInfo
- Publication number
- KR20050037409A KR20050037409A KR1020047005588A KR20047005588A KR20050037409A KR 20050037409 A KR20050037409 A KR 20050037409A KR 1020047005588 A KR1020047005588 A KR 1020047005588A KR 20047005588 A KR20047005588 A KR 20047005588A KR 20050037409 A KR20050037409 A KR 20050037409A
- Authority
- KR
- South Korea
- Prior art keywords
- mycophenolate
- tablets
- solid dosage
- mycophenolic acid
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
Description
Claims (10)
- 미코페놀산 또는 미코페놀레이트 염이 고형 투여 형태의 총 중량을 기준으로 약 20 내지 약 95 중량%의 양으로 존재하는, 약학상 유효량의 미코페놀산 또는 미코페놀레이트 염을 포함하는 고형 투여 형태.
- 제1항에 있어서, 미코페놀산 또는 미코페놀레이트 염이 정제의 총 중량을 기준으로 약 20 내지 약 90 중량%의 양으로 존재하는, (b) 압축 방법에 의한 정제 제조에 적합한 제약상 허용되는 첨가제를 부가적으로 포함하는 정제인 고형 투여 형태.
- 제1항 또는 제2항에 있어서, 결정 형태의 미코페놀레이트 나트륨 염을 포함하는 고형 투여 형태.
- 제1항에 있어서, 무수 형태의 미코페놀산 또는 미코페놀레이트 결정형 일나트륨 염을 포함하는 고형 투여 형태.
- 제1항에 있어서, 추가로 장용피 코팅되어 고형 투여 형태의 총 중량이 장용피를 포함하는 고형 투여 형태.
- (i) 미코페놀산 또는 미코페놀레이트 염과 제약상 허용되는 첨가제를 혼합하고,(ii) 단계 (i)에서 수득한 혼합물을 과립화하고 (단계 (ii)는 임의적임),(iii) 단계 (ii)에서 수득한 과립과 제약상 허용되는 첨가제를 압축하여 정제를 형성하는 방법을 포함하는,제2항에 따른 정제의 제조 방법.
- 제6항에 따른 단계 (i) 및 (ii)에 제시된 방법에 의해 제조된 과립.
- 제6항에 따른 방법에 의해 제조된 정제.
- 임의로 다른 면역억제제와 함께 동시에, 순차적으로 또는 개별적으로 투여하는, 면역-매개성 및(또는) 염증성 질환의 치료 또는 예방, 특히 천연 또는 유전자 도입 기관, 조직 또는 세포 동종 이식 거부반응의 치료 또는 예방을 위한 면역억제용 의약 제조에 있어서의 제2항에 따른 정제의 용도.
- 제1항에 따른 고형 투여 형태를 면역억제가 필요한 대상체에게 임의로 다른 면역억제제와 함께 동시에, 순차적으로 또는 개별적으로 투여하는 것을 포함하는, 대상체를 면역억제하는 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0124953.1 | 2001-10-17 | ||
GBGB0124953.1A GB0124953D0 (en) | 2001-10-17 | 2001-10-17 | Organic Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050037409A true KR20050037409A (ko) | 2005-04-21 |
KR100671367B1 KR100671367B1 (ko) | 2007-01-19 |
Family
ID=9924043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047005588A KR100671367B1 (ko) | 2001-10-17 | 2002-10-16 | 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 |
Country Status (32)
Country | Link |
---|---|
US (3) | US20050013859A1 (ko) |
EP (1) | EP1438040B2 (ko) |
JP (2) | JP2005508959A (ko) |
KR (1) | KR100671367B1 (ko) |
CN (1) | CN1310640C (ko) |
AR (2) | AR036813A1 (ko) |
AT (1) | ATE374023T1 (ko) |
AU (1) | AU2002338897B2 (ko) |
BR (1) | BR0213355A (ko) |
CA (1) | CA2460574A1 (ko) |
CO (1) | CO5390076A1 (ko) |
CY (1) | CY1107841T1 (ko) |
DE (1) | DE60222687T3 (ko) |
DK (1) | DK1438040T4 (ko) |
EC (2) | ECSP024342A (ko) |
ES (1) | ES2292819T5 (ko) |
GB (1) | GB0124953D0 (ko) |
HK (1) | HK1067861A1 (ko) |
HU (1) | HU231114B1 (ko) |
IL (2) | IL160968A0 (ko) |
MX (1) | MXPA04003636A (ko) |
MY (1) | MY139206A (ko) |
NO (1) | NO341804B1 (ko) |
NZ (1) | NZ532280A (ko) |
PE (1) | PE20030476A1 (ko) |
PL (2) | PL415001A1 (ko) |
PT (1) | PT1438040E (ko) |
RU (2) | RU2338528C2 (ko) |
SI (1) | SI1438040T2 (ko) |
TW (1) | TWI333861B (ko) |
WO (1) | WO2003032978A1 (ko) |
ZA (1) | ZA200401977B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
CA2573781A1 (en) * | 2004-07-20 | 2006-02-02 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Processes for preparation of crystalline mycophenolate sodium |
GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
US20060235009A1 (en) | 2005-02-08 | 2006-10-19 | Richard Glickman | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors |
US20060235070A1 (en) * | 2005-02-08 | 2006-10-19 | Hayden Michael R | Compositions and methods for treating vascular, autoimmune, and inflammatory diseases |
BRPI0616640A2 (pt) * | 2005-09-30 | 2011-06-28 | Novartis Ag | combinação de compostos orgánicos |
JP5394746B2 (ja) * | 2005-12-21 | 2014-01-22 | ビーエーエスエフ ソシエタス・ヨーロピア | 錠剤崩壊剤としての微粒子状架橋ポリビニルピロリドン |
CN101378749A (zh) * | 2006-02-13 | 2009-03-04 | 诺瓦提斯公司 | 高剂量的麦考酚酸(mpa) |
CA2686964A1 (en) | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
WO2008148731A1 (de) | 2007-06-06 | 2008-12-11 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
MX2010001711A (es) * | 2007-08-13 | 2010-03-11 | Panacea Biotec Ltd | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
CN101969931A (zh) * | 2008-03-05 | 2011-02-09 | 万能药生物有限公司 | 包含霉酚酸的调节释放药物组合物及其方法 |
JP2011527339A (ja) * | 2008-07-09 | 2011-10-27 | アスプレバ インターナショナル リミテッド | 眼障害を処置するためのミコフェノール酸ナトリウムのpH特異的な溶液 |
EP2488173A1 (en) * | 2009-10-13 | 2012-08-22 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
US20110086102A1 (en) * | 2009-10-13 | 2011-04-14 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
WO2011051967A2 (en) * | 2009-10-23 | 2011-05-05 | Alkem Laboratories Ltd | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof |
GB201100786D0 (en) | 2011-01-18 | 2011-03-02 | Ems Sa | Pharmaceutical compositions of immunosuppressants |
CN102793658A (zh) * | 2012-08-23 | 2012-11-28 | 无锡福祈制药有限公司 | 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片 |
CN103845323B (zh) * | 2012-11-30 | 2018-02-02 | 重庆华邦制药有限公司 | 麦考酚酸及其盐肠溶制剂和制备方法 |
WO2014167442A1 (en) | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Pharmaceutical compositions comprising mycophenolic acid or salts thereof |
CN106727403A (zh) * | 2017-01-03 | 2017-05-31 | 无锡福祈制药有限公司 | 一种麦考酚钠肠溶片及其制备方法 |
WO2018170022A2 (en) * | 2017-03-13 | 2018-09-20 | Okava Pharmaceuticals, Inc. | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals |
CN112218623A (zh) * | 2018-06-14 | 2021-01-12 | 博希尔公司 | 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂 |
RU2723255C2 (ru) * | 2018-11-14 | 2020-06-09 | Общество с ограниченной ответственностью "Изварино Фарма" | Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы |
WO2022162088A2 (en) * | 2021-01-28 | 2022-08-04 | Priothera Sas | Methods of treatment with s1p receptor modulators |
EP4346790A1 (en) * | 2021-05-26 | 2024-04-10 | The Texas A&M University System | Biodegradable mucoadhesive pharmaceutical formulations and methods thereof |
CN117442580B (zh) * | 2023-12-21 | 2024-04-05 | 泊诺(天津)创新医药研究有限公司 | 一种高生物利用度麦考酚钠肠溶片及其制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1157100A (en) † | 1966-09-27 | 1969-07-02 | Ici Ltd | Pharmaceutical Compositions |
GB1157099A (en) * | 1966-09-27 | 1969-07-02 | Ici Ltd | Fermentation Process |
GB1203328A (en) * | 1968-06-04 | 1970-08-26 | Ici Ltd | Pharmaceutical compositions |
US3880995A (en) * | 1973-05-14 | 1975-04-29 | Lilly Co Eli | Treatment of arthritis with mycophenolic acid and derivatives |
JPS56127093A (en) * | 1980-03-10 | 1981-10-05 | Ajinomoto Co Inc | Preparation of mycophenolic acid |
US4725622A (en) * | 1986-01-23 | 1988-02-16 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
US4959387A (en) * | 1986-01-23 | 1990-09-25 | Syntex (U.S.A.) Inc. | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis |
US4748173A (en) * | 1987-01-30 | 1988-05-31 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions |
US5177072A (en) * | 1987-01-30 | 1993-01-05 | Syntex (U.S.A.) Inc. | Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives |
US4753935A (en) * | 1987-01-30 | 1988-06-28 | Syntex (U.S.A.) Inc. | Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions |
EP0670724A1 (en) * | 1992-11-24 | 1995-09-13 | Syntex (U.S.A.) Inc. | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
WO1994012184A1 (en) * | 1992-11-24 | 1994-06-09 | Syntex (U.S.A.) Inc. | Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis |
CZ286051B6 (cs) * | 1993-02-26 | 1999-12-15 | The Procter & Gamble Company | Farmaceutický prostředek a způsob jeho použití pro dasažení projímavého účinku |
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5651983A (en) * | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
DK0721335T3 (da) * | 1993-10-01 | 2006-01-09 | Roche Palo Alto Llc | Orale suspensioner med höj dosis af mycophenolat-mofetil |
JP3725542B2 (ja) * | 1993-10-19 | 2005-12-14 | 大正製薬株式会社 | ピコサルフェート剤形 |
US5514663A (en) * | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
EP1181034B1 (en) * | 1999-05-10 | 2010-07-21 | Paolo Brenner | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
HUP9903226A2 (en) * | 1999-09-23 | 2002-08-28 | Gyogyszerki | Process for producing mycophenolic acid and derivatives thereof |
DE60023187D1 (de) * | 2000-02-29 | 2006-02-23 | Biocon Ltd | Herstellung und reinigung von mycophenolsäure |
GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
-
2001
- 2001-10-17 GB GBGB0124953.1A patent/GB0124953D0/en not_active Ceased
-
2002
- 2002-10-15 AR ARP020103852A patent/AR036813A1/es not_active Application Discontinuation
- 2002-10-15 TW TW091123694A patent/TWI333861B/zh not_active IP Right Cessation
- 2002-10-15 CO CO02092380A patent/CO5390076A1/es not_active Application Discontinuation
- 2002-10-15 PE PE2002001013A patent/PE20030476A1/es not_active Application Discontinuation
- 2002-10-16 HU HU0600451A patent/HU231114B1/hu unknown
- 2002-10-16 WO PCT/EP2002/011589 patent/WO2003032978A1/en active IP Right Grant
- 2002-10-16 PT PT02777314T patent/PT1438040E/pt unknown
- 2002-10-16 DK DK02777314.2T patent/DK1438040T4/da active
- 2002-10-16 US US10/492,289 patent/US20050013859A1/en not_active Abandoned
- 2002-10-16 DE DE60222687.2T patent/DE60222687T3/de not_active Expired - Lifetime
- 2002-10-16 ES ES02777314T patent/ES2292819T5/es not_active Expired - Lifetime
- 2002-10-16 MX MXPA04003636A patent/MXPA04003636A/es active IP Right Grant
- 2002-10-16 CA CA002460574A patent/CA2460574A1/en not_active Abandoned
- 2002-10-16 BR BRPI0213355-5A patent/BR0213355A/pt active Search and Examination
- 2002-10-16 NZ NZ532280A patent/NZ532280A/en not_active IP Right Cessation
- 2002-10-16 KR KR1020047005588A patent/KR100671367B1/ko active IP Right Review Request
- 2002-10-16 PL PL415001A patent/PL415001A1/pl unknown
- 2002-10-16 RU RU2004115332/15A patent/RU2338528C2/ru not_active IP Right Cessation
- 2002-10-16 PL PL367738A patent/PL234541B1/pl unknown
- 2002-10-16 MY MYPI20023865A patent/MY139206A/en unknown
- 2002-10-16 SI SI200230646T patent/SI1438040T2/sl unknown
- 2002-10-16 CN CNB028198611A patent/CN1310640C/zh not_active Expired - Fee Related
- 2002-10-16 IL IL16096802A patent/IL160968A0/xx unknown
- 2002-10-16 JP JP2003535782A patent/JP2005508959A/ja active Pending
- 2002-10-16 AT AT02777314T patent/ATE374023T1/de active
- 2002-10-16 AU AU2002338897A patent/AU2002338897B2/en not_active Expired
- 2002-10-16 EP EP02777314.2A patent/EP1438040B2/en not_active Expired - Lifetime
- 2002-11-19 EC EC2002004342A patent/ECSP024342A/es unknown
- 2002-11-19 EC EC2002004341A patent/ECSP024341A/es unknown
-
2004
- 2004-03-11 ZA ZA200401977A patent/ZA200401977B/en unknown
- 2004-03-18 IL IL160968A patent/IL160968A/en active IP Right Grant
- 2004-05-03 NO NO20041785A patent/NO341804B1/no not_active IP Right Cessation
-
2005
- 2005-01-07 HK HK05100153A patent/HK1067861A1/xx not_active IP Right Cessation
-
2007
- 2007-08-13 RU RU2007130786/15A patent/RU2381026C2/ru not_active IP Right Cessation
- 2007-12-19 CY CY20071101618T patent/CY1107841T1/el unknown
-
2009
- 2009-01-23 JP JP2009012781A patent/JP2009137996A/ja active Pending
-
2010
- 2010-05-03 US US12/772,608 patent/US20100210717A1/en not_active Abandoned
-
2012
- 2012-05-04 AR ARP120101574A patent/AR085778A2/es not_active Application Discontinuation
- 2012-05-29 US US13/482,003 patent/US20120237601A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100671367B1 (ko) | 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 | |
AU2002338897A1 (en) | Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt | |
KR101161283B1 (ko) | 발사르탄의 고형 경구제형 | |
EP3103448B1 (en) | Pharmaceutical compositions comprising an s1p modulator | |
US7727553B2 (en) | Oral preparations with favorable disintegration characteristics | |
US20080206322A1 (en) | Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin | |
ZA200309724B (en) | Oral controlled release pharmaceutical composition for one a day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
MXPA06003646A (es) | Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina. | |
WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
WO2004078111A2 (en) | Extended release minocycline compositions and processes for their preparation | |
US9504655B2 (en) | Capsule dosage form of metoprolol succinate | |
US20150250734A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
SK50222004A3 (sk) | Kompozície matrice s modifikovaným uvoľňovaním, s dlhodobým účinkom | |
WO2023044024A1 (en) | Novel ph dependent coating drug delivery system | |
WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
US20070232697A1 (en) | Method for preparing free base compositions and formulations thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121226 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131219 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141231 Year of fee payment: 9 |
|
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 11 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2015100001592; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327 Effective date: 20170119 |
|
J2X1 | Appeal (before the patent court) |
Free format text: TRIAL NUMBER: 2017200001175; INVALIDATION |
|
FPAY | Annual fee payment |
Payment date: 20180103 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 13 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2017200001175; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20170217 Effective date: 20171222 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2018300010282; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20180131 Effective date: 20191031 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019130000159; TRIAL DECISION FOR INVALIDATION REQUESTED 20191108 Effective date: 20191121 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 14 |
|
G170 | Re-publication after modification of scope of protection [patent] |